期刊文献+

基因重组可溶性非融合血管生成抑制剂Kringle5的色谱分离和纯化 被引量:2

Isolation and purification of recombinant soluble and non-fusion angiogenesis inhibitor Kringle 5 using chromatography
在线阅读 下载PDF
导出
摘要 Kringle 5是血纤维蛋白溶酶原中特异抑制内皮细胞增生和迁移活性最高的一种血管生成抑制剂。该实验在前期成功克隆和表达可溶性非融合血管生成抑制剂Kringle 5的基础上,建立了一种两步色谱法分离纯化Kringle5的方法。首先用SP Sepharose Fast Flow强阳离子交换色谱柱对Kringle 5重组菌体破碎上清液进行初步分离,然后再用丙烯葡聚糖凝胶S-100HR凝胶排阻色谱柱对其进行进一步的纯化。采用本方法得到的可溶性非融合血管生成抑制剂Kringle 5经十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和高效凝胶排阻色谱检测其纯度大于98%,通过鸡胚尿囊膜法确定这种蛋白质具有抑制内皮毛细血管生长的活性。 The Kringle 5 domain of plasminogen is one of the most potent angiogenesis inhibitors known to date,which can inhibit cell proliferation and migration efficiently.In the study,on the foundation of successful clone and expression of recombinant soluble and non-fusion angiogenesis inhibitor Kringle 5,a two-step chromatographic method,including the use of SP Sepharose Fast Flow cation exchanger and Sephacryl S-100 HR size exclusion chromatography in sequence,was established to separate and purify angiogenesis inhibitor Kringle 5.On the SP Sepharose Fast Flow column,the buffer A consisted of 50.0 mmol/L acetic acid-sodium acetate(pH 5.2),and the buffer B consisted of buffer A with the addition of 0.5 mol/L sodium chloride(pH 5.2);on Sephacryl S-100 HR column,the elution buffer was 5.0 mmol/L phosphate solution(pH 7.0).Through the two-step chromatographic purification process,the purity of the obtained Kringle 5 was more than 98%.In addition,it was found that the obtained Kringle 5 could inhibit the blood vessel growth of chick embryo chorioallantoic membrane effectively.Finally it is concluded that this method can effectively separate active recombinant soluble and non-fusion angiogenesis inhibitor Kringle 5.
出处 《色谱》 CAS CSCD 北大核心 2012年第8期822-826,共5页 Chinese Journal of Chromatography
基金 国家"重大新药创制"科技重大专项项目(2009ZX09103696)
关键词 阳离子交换色谱 凝胶排阻色谱 血管生长抑制剂Kringle5 分离 纯化 cation exchange chromatography(CEC) gel exclusion chromatography(GEC) angiogenesis inhibitor Kringle 5 separation purification
  • 相关文献

参考文献13

二级参考文献155

共引文献80

同被引文献32

  • 1陈中举,张燕玲,黄金瑛.荧光标记生物大分子及其应用[J].国外医学(生物医学工程分册),2004,27(6):348-352. 被引量:22
  • 2曲萍,隋延仿,叶菁,张秀敏.增强型绿色荧光蛋白的基因克隆、表达及蛋白纯化[J].陕西医学杂志,2006,35(10):1235-1237. 被引量:3
  • 3叶伟民,韩焕兴,范列英,孔宪涛.Bradford比色法简便、快速测定微量蛋白[J].上海医学检验杂志,1996,11(4):207-208. 被引量:26
  • 4杨保珍,张天民,王树歧.低抗凝肝素修饰超氧化物歧化酶的研究[J].药物生物技术,1996,3(2):82-86. 被引量:9
  • 5Roszkowska W, Worowski K. Heparin [ J ]. Postepy Hig Med Dosw, 1984, 38(1) : 73-124.
  • 6Donayre CE. Current use of low molecular weight heparins[ J]. Semin Vasc Surg, 1996, 9(4) :362-371.
  • 7Kon A , Takagaki K , Kawasaki H, et al. Application of 2- aminopyridine fluorescence labeling to glycosaminoglycans [ J]. J Biochem, 1991, 110(1) : 132-135.
  • 8Roger O, Colliec-Jouault S, Ratiskol J, et al. Polysacehride labeling: impact on structural and biological properties [ J ]. Carbohydr Polym, 2002, 50 (3) : 273-278.
  • 9Chalfie M, Tu Y, Euskirchen G, et al. Green fluorescent protein as a marker for gene expression [ J]. Science, 1994, 263 ( 5148 ) : 802-805.
  • 10Shaner NC, Patterson GH, Davidson MW. Advances in fluorescent protein technology[ J ]. J Cell Sei, 2007, 120 (24) : 4247-4260.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部